Aspire Biopharma Holdings, Inc. ASBP
8.32
(0.38)
(4.37%)
as of 25 Sep
- Market cap
- $12.2M
- P/E
- 0.2×
Follow ASBP
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
228.48% | 618.48% | 576.00% | (1,032.15%) | |
| (453.08%) | (3,353.07%) | (259.01%) | (152.09%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
179.26% | 389.78% | (296.68%) | (93.80%) | |
Average Days of Receivables |
— | — | — | 0.00 | |
Free Cash Flow per Share |
(85.34) | (98.87) | (39.63) | (6.92) | |
Free Cash Flow |
(3.52) | (4.92) | (6.21) | (7.19) | |
Piotroski F-Score |
2.00 | 3.00 | 3.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
107.23% | 190.69% | (63.86%) | (30.04%) | |
Accounts Receivable Turnover |
— | — | — | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.09 | |
Inventory Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 2,903.57 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 861.72 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 857.83% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 6,373.90% | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 161.21% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.17 | 0.20 | 0.53 | 0.65 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.09 | |
Operating CF per Share |
(85.34) | (98.87) | (39.63) | (6.92) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | — | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | (11,309.31%) |
Columns are period end dates